Dental and medical products company Henry Schein (NASDAQ:HSIC) reported Q3 CY2025 results exceeding the market’s revenue ...
Henry Schein, Inc. (NASDAQ:HSIC) is one of the stocks highlighted as Jim Cramer responded to questions from Harvard Business ...
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...
Medical equipment distributor Henry Schein raised its annual profit forecast after beating Wall Street estimates for ...
Following the strong quarterly performance, Henry Schein raised its 2025 adjusted EPS guidance to $4.88-$4.96 from its previous range of $4.80-$4.94, above the analyst consensus of $4.82. The company ...
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) today announced that it has signed a cooperative contract with OMNIA Partners, one of the nation’s largest purchasing organizations ...
At the center of this partnership is Henry Schein One's ambitious global AI strategy - a multi-layered initiative to transform how dental professionals manage their practices and deliver care. The ...
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein Medical, the U.S. medical business of Henry Schein, Inc. (Nasdaq: HSIC), and Medpod Inc. today announced the launch of Medpac – a lightweight, portable ...
MELVILLE, N.Y.--(BUSINESS WIRE)-- Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, today announced the ...
Epica™ Medical Innovations, a leader in innovative imaging and therapeutic solutions for the veterinary market, announced today that Henry Schein Animal Health will be the exclusive distributor of its ...
Medical and dental giant Henry Schein just got a little bigger. On June 21 the $4.6 billion merchant said it would acquire the direct marketing divisions of Darby Group Cos.’ medical and laboratory ...
HSIC heads into Q3 with solid gains expected across Dental, Specialty and Tech segments, though earnings estimates have slipped slightly.